Details for Patent: 11,254,652

Which drugs does patent 11,254,652 protect, and when does it expire?

Patent 11,254,652 protects PYRUKYND and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 11,254,652

Title:	Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfon- amide
Abstract:	Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency. ##STR00001##
Inventor(s):	Sizemore; Jacob P. (Cambridge, MA), Guo; Liting (Suzhou, CN), Mirmehrabi; Mahmoud (Halifax, CA), Su; Yeqing (Halifax, CA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	16/765,456
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 11,254,652

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 11,254,652

PCT Information
PCT Filed	November 21, 2018	PCT Application Number:	PCT/US2018/062197
PCT Publication Date:	May 31, 2019	PCT Publication Number:	WO2019/104134

International Family Members for US Patent 11,254,652

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018373122
Australia	2024200724
Brazil	112020010185